APA (7th ed.) Citation

Liu, D., Yang, Z., Wang, L., Ma, L., Hou, W., Ren, S., . . . Lu, J. (2025). Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: A single-center, retrospective study. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-15126-4

Chicago Style (17th ed.) Citation

Liu, Dan, Zirong Yang, Lilin Wang, Lina Ma, Wei Hou, Shan Ren, Sujun Zheng, and Junfeng Lu. "Comparative Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Antiangiogenic Agents for Unresectable Hepatocellular Carcinoma in Patients with Child-Pugh A Versus B Cirrhosis: A Single-center, Retrospective Study." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-15126-4.

MLA (9th ed.) Citation

Liu, Dan, et al. "Comparative Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Antiangiogenic Agents for Unresectable Hepatocellular Carcinoma in Patients with Child-Pugh A Versus B Cirrhosis: A Single-center, Retrospective Study." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-15126-4.